Du är här

2015-08-19

Apricus Biosciences, Inc.: Apricus Biosciences Announces it is Seeking a Global Partner for Femprox, a Novel Treatment for Female Sexual Dysfunction

SAN DIEGO, Calif., Aug. 19, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
("Apricus" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com)
announced today that it re-affirms its intent to seek a global development
partner for Femprox®, the Company's topical alprostadil cream for the
treatment of female sexual interest/arousal disorder ("FSIAD"). Femprox is a
topically applied formulation of 0.4% alprostadil delivered using Dodecyl
2-(N, N dimethylamino)-propionate (DDAIP), Apricus' proprietary drug delivery
technology. The Company has completed a near 400 subject proof-of-concept
clinical trial on Femprox, which achieved statistical significance in both
its primary and secondary endpoints.

"Given the recent FDA approval of Sprout Pharmaceuticals, Inc.'s flibanserin
for female sexual dysfunction, Apricus now believes that a potential
regulatory path exists in the U.S. for Femprox," said Richard Pascoe,
Apricus' Chief Executive Officer. "We will immediately initiate a disciplined
partnering process to identify potential licensees for the global development
and commercialization rights for Femprox with the goal of maximizing our
return on investment for the potential benefit of shareholders."

About Femprox®

Femprox® is a 0.4% alprostadil cream intended for the treatment of FSIAD. To
date, Apricus Bio has completed nine clinical studies with Femprox, including
one, 98-subject Phase II study in the U.S. and a near 400-subject
proof-of-concept study in China. Femprox exerts a local, relaxant effect on
vulvar and clitoral blood vessels in women, leading to increased blood flow.
The resultant increase in lubrication and sensory feedback is believed to
produce an increase in sexual arousal in women with FSIAD.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (Nasdaq:APRI) is a biopharmaceutical company
advancing innovative medicines in urology and rheumatology. Apricus has
initiated a Phase 2b trial for fispemifene, a selective estrogen receptor
modulator for the treatment of symptomatic male secondary hypogonadism, and
plans to conduct additional studies in other urological conditions. Apricus
recently completed enrollment in a Phase 2a trial for RayVa(TM), its product
candidate for the treatment of the circulatory disorder Raynaud's phenomenon.
Apricus' lead commercial product, Vitaros®, for the treatment of erectile
dysfunction, is approved in Europe and Canada and is being commercialized in
several countries in Europe. Apricus' marketing partners for Vitaros include
Mylan NV, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz),
Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires
Majorelle. Apricus' second-generation room temperature Vitaros is under
development.

For further information on Apricus, visithttp://www.apricusbio.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act, as amended. Statements in this
press release that are not purely historical are forward-looking statements.
Such forward-looking statements include, among other things: references to
the timing and success of any development plan and the regulatory pathway for
Femprox®and Apricus' intent to partner with a third-party to develop Femprox.
Actual results could differ from those projected in any forward-looking
statements due to a variety of reasons that are outside of Apricus' control,
including, but not limited to: Apricus' ability to partner with a third-party
to develop Femprox on favorable terms, or at all; potential changes in
regulatory approval requirements; dependence on any partner for key
development activities, and the potential that a partner will have limited
resources or otherwise not prioritize Femprox relative to its other
development priorities; and the results of any additional clinical trials on
Femprox or other drug candidates targeting FSIAD. These forward-looking
statements are made as of the date of this press release, and Apricus assumes
no obligation to update the forward-looking statements, or to update the
reasons why actual results could differ from those projected in the
forward-looking statements. Readers are urged to read the risk factors set
forth in Apricus' most recent annual report on Form 10-K, subsequent
quarterly reports filed on Form 10-Q, and other filings made with the SEC.
Copies of these reports are available from the SEC's website atwww.sec.govor
without charge from Apricus.

CONTACT: Matthew Beck
mbeck@troutgroup.com
The Trout Group
(646) 378-2933

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Apricus Biosciences, Inc. via Globenewswire

HUG#1946395

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.